http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2611032-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f36edd19f4e10026e4778833f2d84a05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 |
| filingDate | 2006-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7fb69a989abb01d10144825386e481d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6692b413013d309fa67c2ffcee13ee9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5cac36b8b56003aface31e7c11109c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b3c9858628ce43d7dc88907fd40b722 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11ed156747a85373558a5ea575a8dbc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13230d113fec1c0f4348ba25c5ed1149 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_127027bd0e948b4418b81ef164d7f5bb |
| publicationDate | 2006-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2611032-A1 |
| titleOfInvention | 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
| abstract | 2-indolyl imidazo[4,5-dlphenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and/or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias. |
| priorityDate | 2005-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.